January 18, 2017 by Chain Drug Review
Berkeley Research Group, branded drug manufacturers, branded prescription medicines, drug rebates, Pharmaceutical Research and Manufacturers of America, PhRMA, prescription drug sales, prescription drug spending, Stephen Ubl
Featured Articles, Leading Headlines, Pharmacy, Supplier News
WASHINGTON — Branded drug manufacturers are shelling out higher rebates and discounts on medications and seeing their share of prescription drug sales shrink, according to a study commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA). PhRMA said Wednesday that the study, conducted by Berkeley Research Group (BRG), is among the first to gauge
January 9, 2017 by Chain Drug Review
Biogen, George Scangos, Joaquin Duato, Johnson & Johnson, Pharmaceutical Research and Manufacturers of America, PhRMA, PhRMA board of directors, Stephen Ubl
Pharmacy, Supplier News
WASHINGTON — The Pharmaceutical Research and Manufacturers of America has named Joaquin Duato, worldwide chairman of pharmaceuticals as Johnson & Johnson, as chairman of the PhRMA board of directors. Duato previously was chairman-elect on the PhRMA board and succeeds George Scangos, who has stepped down as chief executive officer of Biogen. “In the words of
September 22, 2016 by Chain Drug Review
biopharmaceutical industry, biopharmaceutical researchers and scientists, Pharmaceutical Research and Manufacturers of America, PhRMA, Stephen Ubl
Pharmacy, Supplier News
WASHINGTON — The Pharmaceutical Research and Manufacturers of America (PhRMA) yesterday brought more than 60 researchers and scientists from its member companies to meet with congressional lawmakers. PhRMA said the participants discussed how Congress can help support development of new, innovative medicines for patients in need. “America’s biopharmaceutical researchers and scientists are on the frontlines
September 28, 2015 by Mark Baumgartner and Chain Drug Review
Health Affairs, J. Samantha Dougherty, Laura Miller, Medicaid, medication nonadherence, National Association of Chain Drug Stores, Pharmaceutical Research and Manufacturers of America, prescription drug use, Steve Anderson
2015, Issue 09-28-2015, Issues, News
ARLINGTON, Va. — An examination of data on more than 1.5 million Medicaid enrollees found that when prescription drugs are taken appropriately as prescribed by a physician there is a reduction of other medical costs for certain Medicaid populations. The research, undertaken to examine the impact of changes in prescription drug use on medical costs,
September 28, 2015 by Jeffrey Woldt and Chain Drug Review
Affordable Care Act, health care costs, health care reform, health care spending, J. Samantha Dougherty, Jeffrey Woldt, Laura Miller, National Association of Chain Drug Stores, Pharmaceutical Research and Manufacturers of America, retail pharmacies
2015, Issue 09-28-2015, Issues, Opinion
The major provisions of the Patient Protection and Affordable Care Act have been in effect for almost two years now, enough time to undertake an interim analysis of the controversial law’s impact on the health care system. President Obama and other advocates of the ACA, which since its enactment in March 2010 has withstood two
September 9, 2015 by Chain Drug Review
Health Affairs, J. Samantha Dougherty, Laura Miller, Medical Costs In Medicaid Populations, medication nonadherence, NACDS, National Association of Chain Drug Stores, Pharmaceutical Research and Manufacturers of America, PhRMA, Steve Anderson
Leading Headlines, Pharmacy, Retail News
ARLINGTON, Va. — The National Association of Chain Drug Stores and the Pharmaceutical Research and Manufacturers of America (PhRMA) co-authored a Health Affairs article on research finding that when prescription drugs are taken as directed by a physician, other medical costs are reduced for certain Medicaid beneficiaries. Titled “Increased Use Of Prescription Drugs Reduces Medical
April 17, 2015 by John Schultz and Chain Drug Review
Ian Read, John Castellani, Kenneth Frazier, Pharmaceutical Research and Manufacturers of America, PhRMA
Leading Headlines, Supplier News
WASHINGTON — John Castellani, president and chief executive officer of Pharmaceutical Research and Manufacturers of America (PhRMA), plans to retire next year. PhRMA said Thursday that Castellani’s retirement is slated to go into effect Jan. 1, 2016. “Representing the biopharmaceutical industry has been one of the most rewarding experiences of my career, and I am